Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Pemvidutide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb
    Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb

    13 Nov 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/altimmune-poised-for-1b-opportunity-as-mash-drug-aces-phase-iib

    BIOSPACE
    13 Nov 2025
    Share Share
    Altimmune Show AI-Based Liver Fibrosis Data From Pemvidutide Ph2b
    Altimmune Show AI-Based Liver Fibrosis Data From Pemvidutide Ph2b

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183618/0/en/Altimmune-Presents-AI-Based-Analysis-of-Liver-Fibrosis-Reduction-from-IMPACT-Phase-2b-Trial-of-Pemvidutide-in-MASH-in-Late-breaking-Poster-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Altimmune To Present Phase 2B Pemvidutide Data In MASH At AASLD
    Altimmune To Present Phase 2B Pemvidutide Data In MASH At AASLD

    20 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/20/3169260/0/en/Altimmune-to-Present-Phase-2b-IMPACT-Data-on-Pemvidutide-in-MASH-in-Late-Breaking-Oral-Podium-Presentation-and-Late-Breaking-Poster-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    20 Oct 2025
    Share Share
    Altimmune Names Christophe Arbet-Engels, M.d., Phd CMO
    Altimmune Names Christophe Arbet-Engels, M.d., Phd CMO

    29 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/29/3157611/0/en/Altimmune-Appoints-Industry-Veteran-Christophe-Arbet-Engels-M-D-PhD-as-Chief-Medical-Officer-to-Drive-Next-Phase-of-Clinical-Development-of-Pemvidutide.html

    GLOBENEWSWIRE
    29 Sep 2025
    Share Share
    Altimmune’s Pemvidutide Gets FDA Fast Track in Alcohol Disorder
    Altimmune’s Pemvidutide Gets FDA Fast Track in Alcohol Disorder

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/19/3135602/0/en/Altimmune-Announces-FDA-Fast-Track-Designation-for-Pemvidutide-in-Alcohol-Use-Disorder-AUD.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    Altimmune Predicts MASH Resolution with Pemvidutide at EASL
    Altimmune Predicts MASH Resolution with Pemvidutide at EASL

    08 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/08/3077134/0/en/Altimmune-Presents-New-Analyses-Predicting-High-Rates-of-MASH-Resolution-on-Biopsy-following-Pemvidutide-Treatment-at-the-EASL-International-Liver-Congress.html

    GLOBENEWSWIRE
    08 May 2025
    Share Share